Visitors look at Woojung Bio's sterilization machine for robots that transfer and dispose medical waste at the CPhI Korea 2021 exhibition on Monday. Companies specializing in medical devices and equipment attended the event.
It's been a banner year for Korean biopharmaceutical companies as more have been winning big licensing deals to transfer technologies to global players.
CHA Vaccine Institute submitted a securities registration statement to the Financial Supervisory Service, the vaccine maker said Tuesday.
CJ CheilJedang’s net profit rose 65.5 percent in the second quarter as food sales were steady and the company’s bio business grew rapidly
CHA Vaccine Institute, a vaccine maker that is 46 percent owned by CHA Biotech, is a step closer to going public as its application passed a preliminary screening by the Korea Exchange.
A Celltrion-led fund is investing $47 million in Iksuda Therapeutics to become the largest shareholder of the antibody-drug conjugate (ADC) developer, the pharmaceutical company said Monday.
Following the success of mRNA Covid-19 vaccines like those of Moderna and Pfizer, local companies and the Korean government are rushing investments into the state-of-art vaccine technology.
Dr. Cha Kwang-yul, global research and innovation leader at CHA Medical & Bio Group, has achieved many firsts, especially in the areas of infertility treatment, reproductive medicine and stem cell research.
Samsung Biologics further muddied the waters about an unsourced report of it getting a contract to manufacture Covid-19 vaccines for Moderna, choosing not to definitely deny the news.
Lotte Group may buy a stake in a domestic biopharmaceutical firm.